You are here

P&T May 2011


Determining the mutation status of two genes, EGFR and KRAS, may enable health care professionals to identify which patients with non–small-cell lung cancer are likely to benefit from anti-epidermal growth factor receptor–tyrosine kinase inhibitor therapy rather than from chemotherapy.
An Economic Stimulus Plan for Missouri
Meeting Highlights
Meeting Highlights
46th European Association for the Study of the Liver